Compare Amgen, Inc. (AMGN) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Charles River Laboratories Intl. Inc — how do they compare? Amgen, Inc. trades at $384.5 (market cap $205.32B), while Charles River Laboratories Intl. Inc trades at $278.5 (market cap $13.45B). The key difference: Amgen, Inc. is far larger — about 15.3× Charles River Laboratories Intl. Inc's market cap, and Amgen, Inc. pays a 2.65% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amgen, Inc. for 72 Days and Charles River Laboratories Intl. Inc for 34 Days on average.
| AMGN | CRL | |
|---|---|---|
Market Cap | $205.32B | $13.45B |
Volume | 3,201,007 | 807,963 |
Sector | Health | Health |
52-Week High | $444.12 | $298.58 |
52-Week Low | $271.18 | $145.57 |
Typical Hold Time | 72 Days | 34 Days |
Enterprise Value | $248.64B | $16.28B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $383.13, up 1.8% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a 22.95% net income margin and 91.47% ROE, supported by positive pipeline updates like IMDELLTRA's FDA approval. Analysts maintain a buy consensus with a $393.72 target, highlighting defensive appeal amid market volatility.
Outlook is positive due to earnings momentum and dividend stability, but risks include high debt levels and competitive pressures. The stock offers growth potential from pipeline advancements, yet investors should monitor debt management and regulatory developments for sustained performance.
Charles River Laboratories (CRL) trades at $279.10, up 2.08% today, near its consensus price target of $282.36. The stock exhibits a bullish technical trend, with recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. However, fundamentals show a net loss of $144.34 million in 2025, negative margins, and elevated valuation ratios. Positive news includes operational innovations and conference presentations, but profitability remains a concern.
Outlook: Analyst consensus is strongly bullish with 73% buy ratings, but high P/E and negative ROE signal overvaluation risks. Investment opportunity lies in continued earnings outperformance and strategic initiatives, while key risks include margin pressure, debt levels, and volatile NHP costs. The stock's rally faces a higher bar given current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
